文献速递糖尿病肥胖与代谢综合征

2型糖尿病患者启用钠-葡萄糖共转运蛋白-2抑制剂与其他降糖药后的心血管死亡与患病率(CVD-REAL Nordic):一项多国观察性分析

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
PubMed 文献 · Lancet Diabetes Endocrinol · 2017-08-03

CVD-REAL Nordic为多国观察性分析,纳入丹麦、挪威、瑞典2012至2015年启用降糖药的患者,按倾向评分将SGLT2抑制剂新使用者与其他降糖药新使用者1:3匹配。SGLT2抑制剂使用与心血管死亡、主要不良心血管事件及心衰住院风险降低相关,非致死性心梗、非致死性卒中及房颤无显著差异。

要点

  • SGLT2抑制剂使用与心血管死亡风险降低相关(HR 0.53,95%CI 0.40-0.71)。
  • SGLT2抑制剂使用与主要不良心血管事件风险降低相关(HR 0.78,95%CI 0.69-0.87)。
  • SGLT2抑制剂使用与心衰住院风险降低相关(HR 0.70,95%CI 0.61-0.81)。

核心结论

  • 在心血管风险谱广泛的2型糖尿病患者中,SGLT2抑制剂使用与其他降糖药相比与心血管疾病和心血管死亡减少相关,该发现与高心血管风险患者的临床试验结果一致。

研究设计与样本

  • CVD-REAL Nordic为观察性分析,使用丹麦、挪威和瑞典的处方药登记、死因登记和国家患者登记的个人患者水平数据。
  • 纳入2012至2015年间配取降糖药处方的所有患者,随访至2015年12月31日。
  • 患者分为SGLT2抑制剂新使用者和其他降糖药新使用者,每名SGLT2抑制剂使用者按倾向评分与3名其他降糖药使用者匹配。
  • 匹配后SGLT2抑制剂组n=22830,其他降糖药组n=68490,平均随访0.9年(SD 4.1),共80669患者年,平均年龄61岁(12.0),女性40%(36362/91320),基线心血管疾病患病率25%(22686/91320)。
  • SGLT2抑制剂总暴露时间中94%为达格列净,5%为恩格列净,1%为卡格列净。

主要发现

  • 与其他降糖药相比,SGLT2抑制剂使用与心血管死亡风险降低相关(HR 0.53,95%CI 0.40-0.71)。
  • 与其他降糖药相比,SGLT2抑制剂使用与主要不良心血管事件风险降低相关(HR 0.78,95%CI 0.69-0.87)。
  • 与其他降糖药相比,SGLT2抑制剂使用与心衰住院事件风险降低相关(HR 0.70,95%CI 0.61-0.81;所有P<0.0001)。
  • SGLT2抑制剂使用与其他降糖药相比,非致死性心肌梗死、非致死性卒中或房颤无显著差异。
  • 与其他降糖药相比,SGLT2抑制剂使用与严重低血糖风险降低相关(HR 0.76,95%CI 0.65-0.90;P=0.001)。

关键数值与推荐

  • 心血管死亡:基线有心血管疾病者HR 0.60(95%CI 0.42-0.85),无心血管疾病者HR 0.55(95%CI 0.34-0.90)。
  • 主要不良心血管事件:基线有心血管疾病者HR 0.70(95%CI 0.59-0.83),无心血管疾病者HR 0.90(95%CI 0.76-1.07)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with type 2 diabetes and a high cardiovascular risk profile, the sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have been shown to lower cardiovascular morbidity and mortality. Using real-world data from clinical practice, we aimed to compare cardiovascular mortality and morbidity in new users of SGLT2 inhibitors versus new users of other glucose-lowering drugs, in a population with a broad cardiovascular risk profile. METHODS: CVD-REAL Nordic was an observational analysis of individual patient-level data from the Prescribed Drug Registers, Cause of Death Registers, and National Patient Registers in Denmark, Norway, and Sweden. All patients who filled a prescription for glucose-lowering drugs between 2012 and 2015 were included and followed up until Dec 31, 2015. Patients were divided into new users of SGLT2 inhibitors and new users of other glucose-lowering drugs. Each SGLT2 inhibitor user was matched with three users of other glucose-lowering drugs by use of propensity scores. Hazard ratios (HRs) were estimated by country (Cox survival model) and weighted averages were calculated. Cardiovascular outcomes investigated were cardiovascular mortality, major adverse cardiovascular events (cardiovascular mortality, myocardial infarction, and ischaemic or haemorrhagic stroke), hospital events for heart failure (inpatient or outpatient visit with a primary diagnosis of heart failure), non-fatal myocardial infarction, non-fatal stroke, and atrial fibrillation. We also assessed incidence of severe hypoglycaemia. FINDINGS: Matched SGLT2 inhibitor (n=22 830) and other glucose-lowering drug (n=68 490) groups were well balanced at baseline, with a mean follow-up of 0·9 (SD 4·1) years (80 669 patient-years) and mean age of 61 (12·0) years; 40% (36 362 of 91 320) were women and prevalence of cardiovascular disease was 25% (22 686 of 91 320). 94% of the total SGLT2 inhibitor exposure time was for use of dapagliflozin, with 5% for empagliflozin, and 1% for canagliflozin. Compared with other glucose-lowering drugs, use of SGLT2 inhibitors was associated with decreased risk of cardiovascular mortality (HR 0·53 [95% CI 0·40-0·71]), major adverse cardiovascular events (0·78 [0·69-0·87]), and hospital events for heart failure (0·70 [0·61-0·81]; p<0·0001 for all). We did not identify significant differences between use of SGLT2 inhibitors and use of other glucose-lowering drugs for non-fatal myocardial infarction, non-fatal stroke, or atrial fibrillation. Compared with other glucose-lowering drugs, use of SGLT2 inhibitors was associated with a decreased risk of severe hypoglycaemia (HR 0·76 [0·65-0·90]; p=0·001). For cardiovascular mortality, the differences were similar for the 25% of individuals with cardiovascular disease at baseline and those without (HR 0·60 [0·42-0·85] vs 0·55 [0·34-0·90]), while for major adverse cardiovascular events the HR in the group with cardiovascular disease at baseline was 0·70 (0·59-0·83) versus 0·90 (0·76-1·07) in the group without. INTERPRETATION: In a population of patients with type 2 diabetes and a broad cardiovascular risk profile, SGLT2 inhibitor use was associated with reduced cardiovascular disease and cardiovascular mortality compared with use of other glucose-lowering drugs-a finding consistent with the results of clinical trials in patients at high cardiovascular risk. FUNDING: AstraZeneca.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Birkeland KI, Jørgensen ME, Carstensen B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 2017. PMID: 28781064. doi:10.1016/S2213-8587(17)30258-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。